Quality of life assessment when considering the introduction of device-assisted therapies in advanced Parkinson's disease: A retrospective observational cross-sectional study.

Autor: Ueno T; Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan. Electronic address: tatsuya_ueno@med.pref.aomori.jp., Haga R; Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan., Arai A; Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan., Tomiyama M; Department of Neurology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Jazyk: angličtina
Zdroj: Journal of the neurological sciences [J Neurol Sci] 2024 Feb 15; Vol. 457, pp. 122890. Date of Electronic Publication: 2024 Jan 14.
DOI: 10.1016/j.jns.2024.122890
Abstrakt: Introduction: Device-aided therapy (DAT) is an established treatment for improving the quality of life (QOL) in individuals with advanced Parkinson's disease (APD). Criteria for starting DAT, including motor and non-motor symptoms, have been proposed. However, it remains unclear whether QOL differences among patients with APD influence DAT introduction. Therefore, we aimed to investigate QOL differences between patients with and without DAT introduction.
Methods: This retrospective observational cross-sectional study included 245 patients with PD who were followed up between January 1, 2020, and June 30, 2022. We defined cases that underwent DAT introduction after evaluation as "planned-DAT" and those that did not as "not-planned-DAT." We performed between-group comparisons of the PD questionnaire-39 (PDQ-39) summary index (SI) in patients with APD who met the 5-2-1 criteria (≥5 times the oral levodopa dose/day, ≥2 h of "off" symptoms/day, and ≥ 1 h of troublesome dyskinesia/day).
Results: Seventy-nine patients met the inclusion criteria for APD (median age: 68 [61.0-73.0] years; 62.8% [N = 52] women). The PDQ-39 SI scores were higher in the planned-DAT group (N = 12) than in the not-planned-DAT group (N = 67) (29.2 [22.1-33.6] vs. 19.0 [10.3-49.6] points, P < 0.05). After propensity-score matching according to age and sex, the PDQ-39 SI scores remained higher in the planned-DAT (N = 9) than in the not-planned-DAT group (N = 18) (40.0 [25.4-60.0] vs. 18.5 [7.9-46.8] points, P < 0.05).
Conclusions: Our results suggest that QOL assessment using PDQ-39 can be used to identify patients eligible for DAT.
Competing Interests: Declaration of competing interest None.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: